Gland Pharma Balance Sheet Health
Financial Health criteria checks 5/6
Gland Pharma has a total shareholder equity of ₹83.1B and total debt of ₹3.6B, which brings its debt-to-equity ratio to 4.3%. Its total assets and total liabilities are ₹102.9B and ₹19.9B respectively. Gland Pharma's EBIT is ₹8.6B making its interest coverage ratio -5.3. It has cash and short-term investments of ₹21.4B.
Key information
4.3%
Debt to equity ratio
₹3.57b
Debt
| Interest coverage ratio | -5.3x |
| Cash | ₹21.45b |
| Equity | ₹83.07b |
| Total liabilities | ₹19.86b |
| Total assets | ₹102.93b |
Recent financial health updates
Recent updates
Is Gland Pharma (NSE:GLAND) A Risky Investment?
Mar 19
Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion
Feb 16Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher
May 20Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value
Feb 07Analysts Just Slashed Their Gland Pharma Limited (NSE:GLAND) EPS Numbers
Jul 22Does This Valuation Of Gland Pharma Limited (NSE:GLAND) Imply Investors Are Overpaying?
Jul 14Is Now The Time To Put Gland Pharma (NSE:GLAND) On Your Watchlist?
Feb 08A Look At The Intrinsic Value Of Gland Pharma Limited (NSE:GLAND)
Jul 05Gland Pharma (NSE:GLAND) Strong Profits May Be Masking Some Underlying Issues
May 24Gland Pharma Limited (NSE:GLAND) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 19Gland Pharma Limited's (NSE:GLAND) 27% Price Boost Is Out Of Tune With Earnings
Mar 04Gland Pharma Limited's (NSE:GLAND) Stock Is Going Strong: Is the Market Following Fundamentals?
Feb 20Financial Position Analysis
Short Term Liabilities: GLAND's short term assets (₹59.7B) exceed its short term liabilities (₹15.4B).
Long Term Liabilities: GLAND's short term assets (₹59.7B) exceed its long term liabilities (₹4.5B).
Debt to Equity History and Analysis
Debt Level: GLAND has more cash than its total debt.
Reducing Debt: GLAND's debt to equity ratio has increased from 0.2% to 4.3% over the past 5 years.
Debt Coverage: GLAND's debt is well covered by operating cash flow (109.3%).
Interest Coverage: GLAND earns more interest than it pays, so coverage of interest payments is not a concern.